Merck has rebounded 55% in the past year, driven by optimism around its post-Keytruda strategy despite the looming patent ...
Merck & Co. says it will settle a spate of lawsuits that blame the drugmaker’s blockbuster Gardasil cancer vaccine for ...
Merck (NYSE: MRK), and Pfizer (NYSE: PFE) are among the largest pharmaceutical companies in the world. The first focuses ...
Keytruda continues to shine in solid tumours, and other Merck & Co assets signal designs to address Keytruda's upcoming ...
More biopharma layoffs are hitting New Jersey, this time from Merck & Co.in the latest phase of headcount reductions ...
Morning Overview on MSN
Intismeran autogene plus Keytruda dropped melanoma recurrence by close to 50% over five years in a Moderna-Merck-NYU trial unveiled at ASCO
Patients with high-risk melanoma who received a personalized mRNA cancer vaccine alongside Keytruda saw their risk of disease ...
At a median 5-year (60.3 months) planned follow-up of the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, intismeran autogene in combination with KEYTRUDA demonstrated a 49% reduction in the risk of ...
By Julie Steenhuysen CHICAGO, June 1 (Reuters) - Merck is in discussions with various global health authorities about making ...
Study results accrued so far are giving Merck greater conviction that the therapy, licensed from a China-based biotech, was worth placing into a sprawling Phase 3 program.
Merck reported first-quarter results that topped estimates on strong demand for its cancer immunotherapy Keytruda and some newer products. The pharmaceutical giant also narrowed its 2026 sales ...
The spokesperson said Merck continues to employ more than 8,000 people in New Jersey. Merck has several facilities in eastern ...
Dr. Rasha Kelej Merck Foundation Chief Executive Officer (CEO) and African First Ladies release “Rays of Hope” Animation Film ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results